But Pascal Soriot, chief executive of AstraZeneca, told the Sunday Times: "We think we have figured out the winning formula and how to get efficacy that, after two doses, is up there with everybody else.
Mr Soriot said the earlier results had been seen by the pharmaceutical company as "positive", adding: "They meet the criteria established by regulators around the world.
"We assumed people would be a bit disappointed, that's for sure, but we didn't expect that storm."
"I can't tell you more because we will publish at some point."
The data from the Oxford/AstraZeneca trial has not been as clear as the data from the Pfizer one, which is most likely why approval has been delayed.
Comments by the chief executive of AstraZeneca suggests regulators have been given fresh data, but it is not clear that this information would support plans like the one suggested by Tony Blair, which involve giving children one dose, nor that it will be as efficacious as the other vaccines.
Put another way: there is still some uncertainty about the Oxford vaccine.
Not exactly reassuring any of that. Basically: if you can get a Pfizer vaccine, take it.